Catalyst Financial Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$357K Buy
462
+51
+12% +$39K 0.04% 259
2025
Q4
$317K Buy
+411
New +$279K 0.04% 237
2025
Q1
Sell
-323
Closed -$230K 294
2024
Q4
$230K Sell
323
-6
-2% -$5.04K 0.04% 247
2024
Q3
$346K Buy
329
+3
+0.9% +$3.34K 0.07% 183
2024
Q2
$343K Buy
326
+12
+4% +$11.6K 0.08% 167
2024
Q1
$283K Buy
314
+19
+6% +$18.1K 0.07% 179
2023
Q4
$259K Buy
295
+9
+3% +$7.41K 0.07% 184
2023
Q3
$235K Buy
+286
New +$225K 0.08% 179

Other funds holding REGN

Catalyst Financial Partners's REGN Position: Q1 2026 in Review

Catalyst Financial Partners increased its Regeneron Pharmaceuticals (REGN) stake by 12% in Q1 2026, buying an estimated $39K and bringing the position to 462 shares worth $357K. The position accounts for 0.04% of the portfolio, ranked #259.

Catalyst Financial Partners first reported a position in REGN in Q3 2023 and has held it in 8 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Catalyst Financial Partners held 462 shares of Regeneron Pharmaceuticals worth $357K as of Q1 2026.
  • Catalyst Financial Partners bought 51 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $39K.
  • Regeneron Pharmaceuticals made up 0.04% of Catalyst Financial Partners's portfolio in Q1 2026, its #259 holding.
  • Catalyst Financial Partners first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Catalyst Financial Partners's 13F filing for Q1 2026, filed 12 May 2026.